Botox Use in Fertility Treatment

Safety Profile

Botox acts locally at neuromuscular junctions by inhibiting acetylcholine release, causing localized flaccid paralysis without systemic distribution, as supported by the American Urological Association and the American Academy of Otolaryngology-Head and Neck Surgery 1, 2
The molecular weight of botulinum toxin is extremely high (150,000 daltons), which prevents passage across biological membranes and systemic circulation, according to the Centers for Disease Control and Prevention 3
Botox has been used safely across multiple medical specialties, including treatment of focal dystonia, muscle spasm, and spasticity, with a well-established safety profile, as recommended by the American Urological Association 1, 4

The toxin does not cross into breast milk due to its large molecular weight, suggesting it similarly does not affect reproductive tissues or gametes, as reported by the Centers for Disease Control and Prevention 3

Egg harvesting procedures require 10-14 days of ovarian stimulation from the beginning of menstrual cycle, followed by an outpatient surgical procedure, as outlined by the American Society of Clinical Oncology 5
Botox can be administered before, during, or after this timeline without concern for oocyte quality, as supported by the American Society of Clinical Oncology 5

Proceed with Botox if patient is undergoing or planning egg harvesting for fertility preservation, as recommended by the American Society of Clinical Oncology 5, 6
No contraindications exist for timing relative to ovarian stimulation or concurrent use with fertility medications, as stated by the American Society of Clinical Oncology 5, 6